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Transcatheter treatment of children with congenital heart disease such as coarctation of the aorta and pulmonary artery stenosis
currently involves the use of metal stents. While these provide good short term results, there are long term complications with their
use. Children outgrowmetal stents, obligating them to future transcatheter dilations and eventual surgical removal. A bioabsorbable
stent, or a stent that goes away with time, would solve this problem. Bioabsorbable stents are being developed for use in coronary
arteries, however these are too small for use in pediatric congenital heart disease. A bioabsorbable stent for use in pediatric
congenital heart disease needs to be low profile, expandable to a diameter 8mm, provide sufficient radial strength, and absorb
quickly enough to allow vessel growth. Development of absorbable coronary stents has led to a great understanding of the available
production techniques and materials such as bioabsorbable polymers and biocorrodable metals. Children with congenital heart
disease will hopefully soon benefit from the current generation of bioabsorbable and biocorrodable materials and devices.
1. Introduction
Transcatheter treatment of children with congenital heart
disease using angioplasty and stenting has evolved in recent
years. While rare lesions are successfully treated with angio-
plasty, there is a significant incidence of acute vessel recoil
and late aneurysm formation. The availability of metal stents
can prevent recoil and lessen aneurysm formation. However,
vessels containing a metal stent have a fixed vessel diameter,
and this becomes a problem when placed in rapidly growing
neonates or small children. The stented vessel is unable to
grow with the child leading to a relative restenosis of the
vessel. This obligates the child to require serial redilations,
“unzipping procedures” or even surgical removal. A bioab-
sorbable stent (BAS) would allow for stent placement in small
children without these issues, and it would revolutionize the
treatment of many infants with common forms of congenital
heart disease.
2. Need
Although bioresorbablematerials have been used inmedicine
for several decades, these materials only recently have been
utilized for pediatric transcatheter and surgical vascular and
cardiac devices. Metallic stents are critical in the treatment
of many types of congenital heart lesions such as coarctation
of the aorta and pulmonary artery stenosis, though in most
cases, these devices only need to serve as temporary scaf-
foldings.Their permanent presence can lead to complications
such as thrombosis, late restenosis, and stent fracture. A
biodegradable stent would provide the mechanical support
required to prevent vessel recoil. The stent would then
disappear as the vessel heals and no longer requires structural
support. Once the stent absorbs, the vessel would be able
to grow with child, eliminating the need for future surgery
[1, 2]. Ideally the vessel would regain its vasoreactivity. The
ABSORB trial of the Bioresorbable Vascular Scaffold (BVS)
everolimus-eluting stent, a bioabsorbable stent developed for
use in coronary arteries, showed restoration of a functionally
normal endothelium at the stented site in some patients
[3]. Even in the absence of growth in the target vessel a
bioabsorbable stent would facilitate future intervention such
as angioplasty and would allow for improved access to previ-
ously jailed side branches [4, 5]. Bioabsorbable stents are also
compatible with noninvasive imaging such as MRI and CT
angiography, and they would not hamper future treatment
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options [5–8]. The ideal bioabsorbable stent would provide
enough radial force to resist recoil, would be acceptably
flexible for deployment into the distal pulmonary arteries of a
small child, and should absorb without creating a significant
local inflammatory response or systemic toxicities [4, 5].
It has been hypothesized that structural vascular support
from a pediatric BAS for three to six months will be sufficient
for long term healing [1, 9]. The stent would then lose
structural integrity in nine to 12 months, allowing for vessel
growth. It should be low profile, requiring less than a 6F
sheath for delivery [10]. The ideal pediatric stent length and
diameter are 15mm–20mm and 6mm–9mm, respectively
[10]. The diameter of stents being developed for coronary
arteries is 3-4mm (1), so they are too small for reliable
treatment of most pulmonary artery stenosis and aortic
coarctations.
Reduction or avoidance of stent restenosis is a huge pri-
ority in the treatment of coronary lesions with bioabsorbable
stents, though this could be much less of a concern for
treatment of congenital heart disease. Even in newborns,
these vessels are much larger than coronary arteries and less
prone to severe neointimal hyperplasia and restenosis. Thus,
it is likely that bioabsorbable stents designed specifically for
the aorta and pulmonary arteries in children with congenital
heart disease will be more successful and will not require
drug-eluting agents to be imbedded within the stent matrix.
This paper will review the congenital heart lesions most
commonly treated with stents, the materials and manufac-
turing techniques available for production of bioabsorbable
stents, and the bioabsorbable stents currently under develop-
ment and testing.
3. Coarctation of the Aorta
Coarctation is a narrowing of the aorta typically just after
or close to the origin of the left subclavian artery. Many
coarctations are associated with “ductal” tissue that constricts
the lumen of the aorta as the ductus arteriosus closes. In some
newborns, severe coarctation causes immediate congestive
symptoms, left ventricular failure and can be life threatening.
Mild coarctation can cause progressive hypertension, left
ventricular hypertrophy, and claudication.With an incidence
of 1.5 to 3 per 10,000 live births, coarctation is one of the most
common forms of congenital heart disease [11].
In older children, stenting of coarctation is very simple as
the narrowing can be easily accessed and stented with bare
metal stents from the femoral artery (Figure 1). Stenting in
newborns and smaller children (<15 kg) can often be more
technically challenging, but it is still able to be performed
at relatively low risk to the patient, though surgery remains
the gold standard due to the requirement that current BMS
will need to be redilated at least 3x their initial implantation
size to reach adult size as the child grows. Thus, stenting for
coarctation in infants and smaller children is only performed
as palliation in children deemed too sick for surgical inter-
vention (Figure 2).
Unfortunately, surgical intervention for coarctation in
newborns continues to have significant rates of mortality
(2%), morbidity (up to 12–20%), and failure (recoarctation
up to 18%) [12, 13]. A BRS would allow pediatric interven-
tionalists to offer a very safe, effective, andminimally invasive
approach to pediatric coarctation of the aorta in this high risk
patient population.
In the optimal situation, a bioabsorbable coarctation stent
would be implanted within the coarctation segment at the
time of clinical presentation in the newborn or infant (as was
the case for the BMS shown in Figure 2). The stent would
provide complete relief of obstruction and would allow the
aortic wall to remodel to an appropriate diameter (that of the
stent) after which the stent would degrade. It is presumed
that as the stent naturally degraded and absorbed, the vessel
wall would continue to grow normally without the need
for additional reintervention. An acceptable but less optimal
alternative would be for stent implantation and degradation
as above with a residual relative stenosis in the area of
stenting. This stenosis could be then more easily and safely
treated later with transcatheter methods.
4. Pulmonary Artery Stenosis
Most commonly, pulmonary artery narrowings occur within
the first and/or second arcade branches. They present in one
of three ways: (1) in conjunction with other forms of con-
genital heart disease (most commonly Tetralogy of Fallot),
(2) in patients with well-defined syndromes such as Noonan,
Williams Syndrome, or Alagille Syndrome [14, 15], or (3)
as a consequence of surgery for congenital heart disease.
The most common forms of iatrogenic pulmonary artery
stenosis are from placement of aortopulmonary shunts and
after repair of Tetralogy of Fallot, Transposition of the Great
Vessels, and Truncus Arteriosus. Although pulmonary artery
stenosis is a much more heterogenous disease with great
anatomic variability, pulmonary artery stenosis is currently
the most common indication for use of stents in the pediatric
population. In particular in newborns and small children,
treatment of this disease is limited only by the lack of an
appropriate BAS for pediatric patients.
Similar to the situation with coarctation, use of BMS is
currently considered to be the best treatment for pulmonary
artery stenosis. Unfortunately, as with coarctation, use of
BMS obligates children to serial stent redilation or even
surgical removal in the future (Figure 3). Also, as with
coarctation, results with angioplasty without stenting have
been suboptimal. While proximal branch pulmonary arteries
can be surgically repaired, many of the distal pulmonary
arteries cannot be easily accessed and fixed surgically. Even
repair of proximal pulmonary arteries requires an open chest
operation to be performed on cardiopulmonary bypass with
variable results and high rates of restenosis being observed in
many centers.
BMS used to treat pulmonary artery stenosis is frequently
complicated by “jailing off” side branches that are often
crossed and blocked by metallic stents. A BAS would be
an obviously superior stent for these situations as it could
preserve side branches. A BAS designed for congenital
applications would create a clearly superior device for the





Figure 1: Coarctation (∗) before (a) and after (b) stent (S) placement. This procedure performed by our team provided complete resolution





Figure 2: Newborn coarctation ((a), ∗) effectively treated by our team with a coronary stent ((b), S) in a very ill newborn.This demonstrates





Figure 3: Infant with left PA stenosis before (a) and after (b) stent treatment. Although this provided effective relief of stenosis, this stent
required serial redilation.
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treatment of pulmonary artery stenosis in infants and smaller
children.
There are two main categories of materials available for
production of a stent that will degrade with time. One
category is biocorrodable metal such as magnesium and iron.
The other large category is bioabsorbable polymers [4]. We
will begin by discussing polymers and the stents that have
been produced from polymers to date. We will then discuss
biocorrodable metals and the stents made from them.
5. Composition: Polymers
5.1. Bioabsorbable Polymer Overview. A polymer is a large
molecule made from many smaller units called monomers.
The mechanical properties of a polymer are determined by
many factors in addition to the monomer from which it is
made. Properties such as stiffness, strength, and degrada-
tion time are affected by the number of monomers within
the chain (molecular weight) and the arrangement of the
monomers [16]. In general, the greater the molecular weight
(longer chain of monomers), the greater strength and greater
absorption time the polymer will have [16]. The chain
structure also plays a large role in the strength of a polymer. A
polymer consisting ofmultiple identicalmonomers in a linear
sequence is the most simple and strongest type of polymer.
Chains that are linear can pack themselves in a tight 3D
arrangement, giving them great strength. This is referred to
as high crystallinity. Nonlinear polymer chains have multiple
branches, and the branches prevent the polymer from tightly
packing. These highly branched polymers have a lower
degree of crystallinity and less strength [16]. A polymer’s
properties are also affected by the chain’s sequence isomerism,
stereoisomerism, and addition of different end groups. Two
different monomers can be combined to synthesize copoly-
mers, which will have their own unique properties. Blending
other materials with the polymers and adding catalysts to
the polymer are additional methods available to manipulate
polymer properties [16].
In addition to understanding a polymer’s mechanical
properties, it is important to understandhow the polymerwill
degrade. All polymers degrade to some extent, but a polymer
is only considered bioabsorbable if it is absorbed relatively
quickly—during or immediately after its intended application
[17]. The absorption process consists of two phases: degra-
dation and erosion. Degradation is the process in which
the polymer chain is cleaved into smaller oligomers and
monomers. Bioabsorbable polymers consist of hydrolysable
bonds,making hydrolysis themost importantmode of degra-
dation. Erosion is the process in which material is lost from
the polymer as monomers and oligomers leave the polymer
through pores and cracks created during degradation [17].
The rate of hydrolysis is determined in part by the class
of bond linking the monomers together to form the polymer.
Three common classes of bioabsorbable polymers are poly-
anhydrides, polyorthoesters, and polyesters. They each have
significantly different degradation half-lives.The in vitro half-
life of polyanhydrides is less than 10 minutes, while the half-
life of polyesters is 3.3 years [17]. The rate of each polymer’s
degradation can be altered. Altering the pH, adding enzymes,
catalysts, hydrophilic or hydrophobic end groups, and adding
a copolymer are all ways to adjust the degradation rate
and half-life of the polymer so it better serves its intended
application [17]. Models have been developed to simulate
the mechanical behavior of bioabsorbable polymers as they
degrade. Vieira et al. showed that the decrease in tensile
strength of the copolymer PLA-PCA follows the same trend
as the decrease in molecular weight, so a first order equation
can be used to model the change in mechanical properties
with degradation [18]. This model is helpful when choosing
a polymer for bioabsorbable stent development. Once a
material has been chosen and a prototype stent is made,
extensive in vitro testing of the stent is performed. The stents
are placed in saline baths mimicking an in vivo environment,
and their thickness, weight, and radial strengths aremeasured
over time.
While the mechanical properties of polymers can be
manipulated, it remains difficult to create a stent with the
same radial force and limited recoil compared tometal stents.
To achieve the necessary strength, polymer based stents have
more bulk than metal stents, containing struts that are at
least 150 𝜇m (microns) thick [9]. Polymer based stents have a
larger crossing profile and require a larger sheath for delivery
compared to metal stents [9]. As previously mentioned, a
stent intended for use in babies needs to be low profile to
avoid femoral arterial or venous damage from a large sheath.
This may be one of the largest challenges in developing a
polymer based bioabsorbable stent for use in the pediatric
population.
5.2. Poly(L-Lactic Acid) PLLA. PLLA is the polymer most
commonly used for the production of bioabsorbable stents.
PLLA is an aliphatic polyester composed of the L-enantiomer
of lactic acid (2-hydroxy propionic acid) [19]. It is a well-
studied, high strength, thermoplastic polymer that can be
processed with injection molding, blow molding, thermo-
forming, and extrusion applications [19]. The polymer has
a glass transition temperature of 55 degrees Celsius. This is
the temperature at which there is a reversible transition of a
polymer from a relatively hard state into a rubber-like state.
PLLA has a melting point of 175 degrees Celsius, and it must
be heated to 185–190 degrees Celsius for processing. PLLA
begins to lose molecular weight via chain scission reactions
and thermal degradation when heated to 185 degree Celsius,
so there is a narrow window of processing [19]. Addition of
a small amount of the D-enantiomer improves the polymer’s
processability by depressing the melting point; however, this
also decreases the polymer’s crystallinity [19].
PLLA is degraded by simple hydrolysis of the ester bond,
and it is then metabolized via the Krebs cycle into water
and carbon dioxide [4, 5] (Figure 4). There are five stages of
bioresorption, which can overlap. The first step is absorption
of water from the surrounding tissue. The second phase is
depolymerization by hydrolysis which results in a loss of
molecular weight. The third phase is fragmentation of the
polymer into segments of low-molecular weight polymer
resulting in loss of mass. At this point the polymer no longer












Figure 4: Hydrolysis of PLLA into lactic acid, which is further metabolized into carbon dioxide and water.
has radial strength. There is scission of chains linking the
crystalline regions, and the shorter chains diffuse out of
the device. The small polymers are engulfed by cells using
phagocytosis and subsequently metabolized to L-lactate and
converted to pyruvate. The pyruvate is broken down into
carbon dioxide and water via the Krebs cycle [20].The degra-
dation time is dependent on molecular weight, crystallinity,
temperature, impurities, and catalyst concentration [19].
Addition of the D-enantiomer to the polymer will alter the
mechanical properties, processing temperatures and degree
of crystallinity [19]. PLLA is soluble in organic solvents such
as benzene, chloroform, and tetrahydrofuran [19]. PLLA of
varyingmolecular weight and crystallinity is readily available
for purchase from labs across the world. Companies such as
Teleflex Medical OEM, Synterra, and Goodfellow sell PLLA
online for anywhere from $300 to $500 per kilogram.
The first bioabsorbable stent placed in humans was the
Igaki-Tamai stent (Figure 5). It is made of high molecular
weight (321 KDa) PLLA, which is radiolucent and contains
two radio-opaque gold markers [4, 21]. It has a zig-zag helical
coils with straight bridges design which provides a stent-to-
artery coverage ratio of 24%. Its strut thickness is 170 𝜇m
[22]. It is a hybrid self-expanding stent that is mounted on
a standard angioplasty balloon. The self-expansion requires
heat. A delivery balloon filled with contrast heated to 70
degree Celsius triggers the initial expansion, and the final
self-expansion occurs within 20 to 30 minutes of deployment
when the stent is at body temperature. The FIM study
demonstrated continued expansion of the stent for three
months after deployment and no significant inflammatory
response. The stent provides radial support for 6 months
and appears completely absorbed by IVUS 2-3 years after
deployment [23].
A second version of the stentwas createdwhich contained
Tranilast, an antiproliferative tyrosine kinase inhibitor. This
stent causes significantly less neointimal formation than
the original stent [23]. The stent is not currently being
used in coronary arteries, and this is likely secondary to
the complicated delivery methods requiring heat for self-
expansion.
The Absorb Bioresorbable Vascular Scaffold (BVS)
(Abbott, Santa Clara, CA) is the most advanced, well-studied
bioresorbable vascular scaffold. Absorb is referred to as
a scaffold to indicate its temporary nature in contrast to
a permanent metallic stent. A small mesh tube, the BVS
backbone, is made from poly(L-lactide) (PLLA), and it is
covered with a layer of poly(D,L-lactide) (PDLLA) which
releases everolimus, an antiproliferative medication. The
scaffold is balloon expandable and has two platinum radio-
Figure 5: The Igaki-Tamai stent.
opaque markers [4, 22]. The initial design, available in
3.0mm diameter and 12mm and 18mm lengths, had a
scaffold of circumferential out-of-phase zigzag hoops with
straight and direct links. Its strut thickness was 158𝜇m, the
crossing profile was 1.4mm, and the stent-to-artery coverage
was 25% [22]. To retard physical aging of the polymer,
the BVS was stored at −20 degrees Celsius and had a shelf
life of 8 weeks [5]. It was implanted in 30 patients as part
of the ABSORB Cohort A trial and was found to provide
mechanical support to the coronary artery for a few weeks,
while its degradation time was two years [24, 25]. During
follow-up, patients were administered pharmacological
agents aimed at assessing vessel motion, and preliminary
evidence suggested that natural vessel motion was restored,
which has been hypothesized to improve long-term clinical
outcomes [26].
Based on the knowledge generated during the Cohort
A phase of the ABSORB trial, Abbott made modifications
to the Absorb BVS focused on increasing the duration
of vessel support without compromising other key design
parameters. The product is now available in multiple sizes,
including 2.5mm, 3.0mm, and 3.5mm diameters and 12, 18,
and 28mm lengths [27]. (Figure 6). It fully resorbs within
3 years and provides mechanical support for up to 6–12
months [22, 28]. The product no longer requires subambient
storage, an important feature for large-scale manufacturing
and distribution.
The BVS is produced in Abbott’s Temecula, California
manufacturing facility. PLLA resin is melted and extruded
into thick-walled, small diameter tubes. These tubes are
subsequently heated and expanded into thin-walled, larger
diameter tubes, imparting the material properties essential
to product performance. The tubes are laser cut into the
scaffold pattern, platinum markers are added to provide
radio-opacity, and the stent is crimped onto the balloon
catheter delivery system. Product quality is assessed during
each step of the manufacturing process [29].
Results from the second Cohort B phase of the ABSORB
trial were recently presented at the 62nd Annual Scientific
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Figure 6: The Absorb Bioresorbable Vascular Scaffold.
Session of the American College of Cardiology. The rate of
major adverse cardiovascular events (MACE) in 101 patients
was 10% at the 3-year follow-up, results that are similar
to those of best-in-class drug eluting stents [30]. Abbott
is currently engaged in several clinical trials around the
world with enrollment targeting more than 12,000 patients
[5]. Abbott’s BVS is commercially available in Europe, the
Middle East, and parts of Asia and Latin America. In January
2013, Abbott announced the initiation of ABSORB III, a
randomized clinical trial of more than 2,000 patients that will
support regulatory filings for approval of Absorb in the USA.
It is hoped that the expertise obtained by Abbott in the
manufacturing and testing of the BVS stent can be used to
produce a larger diameter version acceptable for use in pedi-
atric stenting. Abbott is now developing “peripheral” large
diameter PLLA stents to target peripheral arterial disease.
These devices could also be ideal for pediatric indications, but
data is not yet available on these devices.
5.3. Tyrosine Polycarbonate Polymer. The REVA stent (Reva
Medical Inc., San Diego, CA) is an absorbable stent made
from a poly(desaminotyrosil-tyrosine ethyl ester) carbonate
developed at Rutgers University [31]. It contains iodine to
increase its radio-opacity [4, 5]. The tyrosine polycarbonate
polymer is metabolized to water, carbon dioxide, ethanol,
and the iodinated desaminotyrosyl-tyrosine. The iodinated
amino acid is then absorbed and discreted [5]. The polymer
has a slide and lock design which provides good radial force
and flexibility as it can be expanded without material defor-
mation (Figure 7).The strut thickness is 200 𝜇m, the crossing
profile is 1.7mm, and the stent-to-artery coverage is 65%.
Delivery requires a 7F guide. Full degradation time for the
stent is about three years [22]. When tested in the RESORB
human trial, there was a high restenosis rate secondary to
focal mechanical failures [4]. The polymer and slide-and-
lock design was revised, and the updated ReZolve stent has
improved strength and a coating of sirolimus [4, 5]. The
ReZolve stent is currently being evaluated in the RESTORE
Figure 7: ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaf-
fold with slide and lock mechanism.
study which was initiated in 2011 in Europe and Brazil [27].
Another redesign, the ReZolve 2 Scaffold, was developed and
is undergoing initial testing (Figure 7). It utilizes an improved
tyrosine polycarbonate polymer that provides a 30% increase
in radial strength. It is also lower profilewith a crossing profile
of 1.52mm and is 6F compatible [27]. Although the use of
a poly(desaminotyrosil-tyrosine ethyl ester) carbonate for a
pediatric BDS is provocative, the Reva stent design cannot be
easily translated into a larger diameter stent design needed
for pediatrics without a prohibitively large crossing profile.
Although the “slide and lock” design provides excellent radial
force, use of this material or stent design in pediatrics will
require a major strut redesign.
5.4. Poly(Caprolactone) (PCL). PCL is a polyester which has
been used in bioabsorbable medical applications. It is a semi-
crystalline polymer with good flexibility and a low melting
point of approximately 60 degrees Celsius. It is nontoxic
and causes minimal local inflammation during degradation.
Compared to PLLA, PCL has less crystallinity and faster
degradation times [31, 32]. A balloon expanding stent was
designed from PCL at Chang Gung University which has a
slide and self-locking mechanism, similar to the REVA stent
previously discussed [33]. The stent consists of 2 elements,
each an ellipse connected by two rings. The elements were
produced by a lab-made microinjection molding machine.
The stent elements were then interconnected, the assembly
was rolled into a tube, and the connecting points were
welded together with hot spot welding. The stents were then
spray coated by a lab made device with poly(D,L)-lactide-
coglycolide (PLGA) mixed with paclitaxel, an antiprolifera-
tive agent. In vitro testing showed that the stents had good
compression strengths, similar to those of stainless steel
stents, and there was minimal recoil after expansion. The
compression strength and collapse pressures of the stent did
not significantly decrease after 12weeks in a solution designed
to simulate the in vivo environment. The crystallinity of the
PCL in the finished stent was lower than the crystallinity of
the purchased PCL, suggesting that the cold mold processing
technique decreased the polymer’s crystallinity [33]. To our
knowledge there has been no human trial with this stent.
5.5. Poly(Anhydride Ester) Salicylic Acid. The IDEAL stent
(Bioabsorbable Therapeutics Inc, Menlo Park, CA) is a
balloon expandable stent made of salicylic acid (an anti-
inflammatory agent) and a poly(anhydride ester). The
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stent back-bone polymer structure is repeating salicylate
molecules. During absorption bonds between the salicylic
acid and linker molecules are hydrolyzed and salicylic acid
is released. The stent back-bone is covered in an 8.3 𝜇m thick
coating of polymer containing sirolimus [1, 5]. The design is
a tube with laser cut voids. The strut thickness is 200𝜇m,
the crossing profile is 2mm, and the stent-to-artery coverage
ratio is 65%. It provides radial support for 3 months, and the
degradation time is 9 to 12months. Salicylic acidwas included
to reduce local inflammation in addition to the antiprolif-
erative properties of sirolimus. The WHISPER trial was the
first human study. The stent provided good radial strength;
however, significant neointimal growth was observed. A new
stent with thinner struts, an improved design and a slower
drug release is under development. The new design also has
a lower profile making it 6F compatible [5, 34].
6. Composition: Biocorrodable Metal
Whilemost of the work on bioabsorbable stents is being done
with polymers, biocorrodablemetals do have advantages over
polymers. Stentsmade frombiocorrodablemetal tend to have
greater strength and are lower profile compared to polymer
based stents. In this way, they are very similar to traditional
bare metal stents and present less of an engineering challenge
compared to polymer based stents. We will discuss the most
common biocorrodable metals and the stents produced from
them to date.
6.1. Magnesium Alloy. Magnesium is a biocompatible metal
that corrodes in the body and combines with other elements
to form magnesium oxide and organic salts. Magnesium’s
role in biological systems is well understood. 50% of the
total body magnesium is found in bone, and it helps keep
bones strong. It also supports a healthy immune system, helps
maintain normal muscle and nerve function, and plays a role
inmaintaining a normal heart rhythm [9, 35, 36].The amount
of magnesium in currently developed stents ranges from 3 to
6mg.The amount of releasedmagnesiumhas almost no effect
on the plasmamagnesium concentrationwhen absorbed over
a period of months, and any increase in plasma magnesium
would likely be beneficial rather than toxic [9]. Magnesium
is antithrombogenic. It is also a systemic and coronary
vasodilator which decreases systemic vascular resistance
and increases the cardiac index [37]. Early experience with
magnesium alloy stents suggest that the corrosion is well
tolerated with very little associated inflammatory response
[5, 9, 38]. An in vitro study by Sternberg et al. demonstrated
that elevatedmagnesium levels in coronary artery endothelial
and smooth muscle cells may actually have a beneficial effect
in the setting of vessel injury. The data suggests magnesium
decreases smooth muscle cell proliferation and increases
endothelial cell proliferation [39].
The AMS-1 bioresorbable stent (Biotronik, Berlin, Ger-
many) is a balloon expandable, radiolucent stent composed
of 93% magnesium and 7% rare earth metals [5]. It is laser
cut and polished from theWE-43 magnesium alloy tube into
sinusoidal in-phase hoops liked by straight bridges. Strut
thickness is 165 𝜇m, its crossing profile is 1.2mm, it is 6F
compatible, and its stent-to-artery coverage ratio is 10% [1,
22]. The fully expanded stent diameters are 3.0 and 3.5mm,
and the lengths are 10mm and 15mm [31]. It is radiolucent
and does not contain radio-opaque markers. Clinical trials
demonstrated it has good initial radial strength (0.8 bar),
similar to traditional stainless steel stents; however, it only
provides radial support for 1 to 2 weeks [4, 40]. In the
PROGRESS AMS trial, the stent was almost undetectable
by intravascular ultrasound four months after deployment.
There were high rates of restenosis secondary to the very
rapid degradation of the stent [41]. The stent was redesigned
multiple times to increase degradation time and incorporate
drug elution. The second design (Magic) used a different
magnesium alloy (>90% magnesium, zirconium, yttrium,
and rare earth metals), and different design with a square
cross sectional shape of the strut and a reduced strut thickness
of 120𝜇m[22]. It is a premounted stent that is compatiblewith
6F introducer systems [9].
Research has shown that coating magnesium with
biodegradable polymer is an effectivemethod to slowmagne-
sium’s corrosion and loss ofmechanical strength [41]. A study
was performed comparing the degradation under cell culture
condition of magnesium to magnesium covered in different
types of biodegradable polymers [42]. The high molecular
weight PLLA coated magnesium had a significantly lower
corrosion rate compared to uncoated magnesium, and it
showed the most uniform corrosion compared to lowmolec-
ular weight PLLA coating and PCL coating. They concluded
high molecular weight PLLA coating is a suitable option for
slowing the corrosion of magnesium [42]. Another study
showed PLLA and PCL can be applied to magnesium by
spin coating. This study showed low molecular weight PLLA
film had better adhesion strength to magnesium than the
high molecular weight PLLA or PCL but concluded that
both PLLA and PCLA are promising materials for protective
coating [43].
The redesign of the AMS stent from Biotronik, the AMS-
3 or DREAMS stent (Drug Eluting Absorbable Magnesium
Scaffold), is covered with a layer of polymer to slow the
degradation time and allow for Paclitaxel release (Figure 8).
It is 6F compatible.The available diameters are 3 and 3.5mm;
however, it can be overexpanded up to 5mm and still
provide mechanical support [27]. During the first 3 months
after implantation the polymer layer remains stable while
the magnesium gradually begins to degrade. At 6 months
the magnesium degradation is complete and the polymer
absorption is ongoing. At 9months the polymer is completely
absorbed and structural disintegration begins. The Biosolve
study is the first in-man study, and it showed improved
mechanical properties with less early restenosis compared to
the AMS-1 stent at 6-month follow-up [40, 44–46]. Biotronik
is currently developing a second generation DREAMS stent
that has an improved 6-crown 2-link design and is coated in
PLLA carrying sirolimus. The new design provides greater
radial stiffness and mechanical strength for a longer period
of time. It also allows for increased postdilatation capabilities
[27]. The radial stiffness of the 2nd generation DREAMS
stent is comparable to metal stents, at 1.38N/mm [27]. It
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contains radio-opaque markers and elutes sirolimus [27]. A
clinical trial, BIOSOLVE-II, will commence in 2013 pending
preclinical results [27].
More importantly, magnesium based biocorrodable
stents are already being used in select cases in Europe for the
treatment of pulmonary artery stenosis and aortic stenosis
in infants. There are already several published case reports
describing the use of magnesium stents in the pediatric
population. Zartner et al. reported the first placement of
a magnesium stent in the left pulmonary (LPA) artery of
a 1.7 kg preterm baby born at 26-week gestation. The LPA
had been inadvertently ligated, and a 3mm × 10mm AMS-I
stent was successfully placed in the LPA in a hybrid fashion
with a surgical cut-down of the pulmonary bifurcation. At
4-month follow-up the stent had completely degraded and
the left lung continued to be well perfused. Despite the
baby’s small size, the stent was well tolerated without signs
of local or systemic toxicity [47]. About 5 months after stent
implantation the patient died from severe pneumonia. On
autopsy the inner surface of the vessel was endothelialized
with a smooth surface. The inner diameter of the lumen
where the stent had been placed measured 3.7mm. There
were no visible or palpable pieces of the magnesium stent.
Neointimal proliferation measured 100𝜇m at its thickest, but
there was no evidence of inflammatory reactions [2].
Schranz et al. reported the first use of a magnesium
stent for treatment of coarctation of the aorta. A 15-day-
old newborn developed severe long segment recoarctation
after surgical coarctation repair. The baby was too unstable
to tolerate repeat surgery. A 3.5mm × 15mm magnesium
stent (AMS-1, Biotronik, Germany) was deployed with a
16 atm inflation which resulted in a final diameter of 4mm.
The coarctation reoccurred as the stent degraded, so a sec-
ond magnesium stent was placed. Serum magnesium levels
remained within normal limits even after placement of the
second stent. At 3months of age the baby had surgical closure
of a ventricular septal defect. The aorta appeared widely
patent at that time, but the surgeon decided to patch augment
the previously stented aortic segment. For this reason no
long-term follow-up is available [48].
6.2. Iron. Iron was the first metal used to make a biocorrod-
able stent. Iron stents have been placed in animals; however,
none have reached clinical trials. The NOR-I stent (Devon
Medical, Hamburg, Germany) is a balloon expandable stent
that was placed in the descending aorta of New Zealand
white rabbits [49]. Commercially available tubes consisting
of 99.8% iron (Goodfellow, Cambridge, UK) were laser cut
with a stent design similar to a stainless steel coronary stent
(PUVA-AS16). To prevent corrosion, the tubes were laser cut
in a nitrogen atmosphere.Theywere then electropolished to a
strut thickness of 100–120𝜇m.The expanded diameter of the
stents ranged from 3 to 6mm. No significant inflammation
or neointimal formation was seen, there was minimal stent
recoil, and there was no in-stent stenosis or thrombus
formation at 18-month follow-up [49]. At 18 months the
stent struts were still intact; however, there was some sign of
degradation on histological evaluation [49].
A second similar iron stent was developed from 99.5%
iron tubes purchased from Goodfellow Inc. (Huntingdon,
UK). Additional contents of the tube included Aluminium,
Calcium, Cobalt, Chromium, Copper, Mangenese, Nickel,
Selenium, Carbon Phosphate, and Sulphur. The tubes were
laser cut to a similar slotted tube design used in the Saxx stent
(CR Bard, Tempe, AZ, USA) and were electropolished to a
strut thickness of 120𝜇m. The author’s intention was to test
an iron stent that could be implanted in a pediatric patient
with congenital heart disease, so a larger stent diameter was
chosen. The expanded diameters of the stents ranged from
6mm to 12mm. They were placed in the descending aortas
of swine which were followed for up to one year. Results
were similar to the NOR-I stent: the stents performed well
without significant recoil or in-stent stenosis. There was no
more local inflammation or neointimal formation compared
to traditional stainless steel stents, and histopathological
examination of all major organs showed no signs of iron
related toxicity or overload. At one-year follow-up, large
portions of the stent remained intact [50].
There are several advantages to using iron as a material
for biocorrodable stents. Its mechanical properties are similar
to those of traditional stainless steel stents. Iron is radio-
opaque, so addition of markers to make the stent visible
by fluoroscopy is not necessary. Compared to magnesium-
based alloys, iron has a higher ductility so the laser cutting
is less complicated. Iron is less brittle than magnesium, so
iron stents can bemadewith thinner struts.The interaction of
iron with the body, including its transportation and storage,
is well understood. These stents contain only 40mg of pure
iron, about the recommended monthly intake of iron, so
it should have good biocompatibility [51]. In the published
animal studies, iron stents did not cause local or systemic
toxicity from corrosion products, and they did not cause
significant neointimal proliferation. They also performed as
well as traditional stainless steel stents without significant
restenosis. The iron stents degraded very slowly; however,
design modification would be needed to expedite the degra-
dation process for use in the pediatric population.
Possible modifications include using iron based alloys,
thinner struts, or a stent with designed areas of weakness
resulting in stent fragmentation after endothelialization [49,
50]. A stent made from an iron-manganese alloy is being
developed by powder metallurgy. In vitro studies show that
this alloy has goodmechanical properties and degrades faster
than pure iron [52]. Electroformed iron is a material that
may be very suitable for a bioabsorbable stent. Electroforming
is a process that uses electrodeposition to produce metallic
parts. The structure is formed atom layer by atom layer, so it
is ideal for creating thin walled structures with dimensional
precision [53]. A study was done to evaluate the feasibil-
ity of using electroformed iron to create a bioabsorbable
stent. Flat sheets of electroformed iron were created, and
the mechanical properties, microstructure, and corrosion
behavior of these sheets were compared to pure iron and
stainless steel.The electroformed foilsmeasured 100𝜇m thick
and yielded strength comparable to that of stainless steel. It
exhibited a higher corrosion rate compared to CTT-Fe pure
iron, and a lower corrosion rate compared to magnesium.
BioMed Research International 9
DREAMS crimped (3 mm nominal)
(a)
Expansion to 3 mm 
(b)
Overexpansion to 5 mm 
(c)
Figure 8: Biotronik DREAMS stent shown while crimped, expanded to 3mm, and overexpanded to 5mm.
These properties make it a good candidate for application as
a biocorrodable stent material [54].
A numerical model has been developed to predict the
effect of corrosion on the mechanical properties of metallic
bioabsorbable stents. Metallic foils were studied, but the
model is applied in such a way to allow analysis of complex
three-dimensional structures.Themodel is able to predict the
performance of a bioabsorbable metallic stent as it corrodes
over time [55].
7. Conclusion
There is a need for a bioabsorbable stent for use in children
with congenital heart disease. We currently have absorbable
stents for use in adult coronary artery disease which are
not yet FDA approved. The largest expanded diameter of
these stents is generally 4mm. Treatment of coarctation of
the aorta or pulmonary artery stenosis in a newborn would
require a stent which can be expanded to 6–8mm. The stent
needs to be low profile to minimize vessel injury. While the
bioabsorbable coronary stents are relatively low profile, a
larger version of the same stent design that could be expanded
to 8mm would be higher profile. The stents need to be
redesigned to maintain adequate radial strength and have a
larger expanded diameter without a larger crossing profile.
It needs to have the mechanical strength to prevent vessel
recoil, while also absorbing in a short enough time to allow
vessel growth. Development of absorbable coronary stents
has led to a great understanding of the available materials
and production techniques, and children with congenital
heart disease will hopefully soon benefit from the current
generation of bioabsorbable and biocorrodable materials and
devices.
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